Alkermes   1Q Revenues: $161.2 million (+24%) 1Q Loss: $30.7 million (loss of $24.4 million in 1Q14) Comments: Manufacturing and royalty revenues from the company’s long-acting atypical antipsychotic franchise, RISPERDAL CONSTA and INVEGA SUSTENNA/XEPLION were $46.9 million, down 5%. Manufacturing and royalty revenues from AMPYRA/FAMPYRA were $36.5 million, up 77%. Sales of VIVITROL were $31.1 million, up 82%. R&D expenses were up 35% to $70.3 million....